An in vivo genome-wide shRNA screen identifies BCL6 as a targetable biomarker of paclitaxel resistance in breast cancer.
Sultan M, Nearing JT, Brown JM, Huynh TT, Cruickshank BM, Lamoureaux E, Vidovic D, Dahn ML, Fernando W, Coyle KM, Giacomantonio CA, Langille MGI, Marcato P.
Sultan M, et al. Among authors: fernando w.
Mol Oncol. 2021 Aug;15(8):2046-2064. doi: 10.1002/1878-0261.12964. Epub 2021 May 18.
Mol Oncol. 2021.
PMID: 33932086
Free PMC article.